Human Longevity, Inc. Announces Research Fellows Program

Human Longevity, Inc. Announces Research Fellows Program
Program Gives Experts from Several Disciplines Unique Opportunity to Advance Human Genomic Understanding
Application Deadline is September 1, 2015

LA JOLLA, CA – Human Longevity, Inc. (HLI), the genomics-based, technology-driven company, announced today the HLI Research Fellows Program, designed to engage experts in the fields of genomics, informatics/bioinformatics, and machine learning to explore the latest findings and knowledge on genetics with clinically relevant outcomes.  The program gives scholars a unique opportunity to participate in innovative analysis of large scale genome data and to work with groups of scientists, bioinformaticians and machine learning specialists to ensure state-of-the-art annotation and interpretation of the human genome.

HLI is working to revolutionize the practice of medicine by building the world's largest, most comprehensive database of whole genome, phenotype and clinical data.  From there, HLI's team develops and applies large scale computing, machine learning, and scientific analysis to make novel discoveries.  The company is enabling pharmaceutical companies, insurers and healthcare providers to impact and improve health.

"The HLI Research Fellows Program invites leaders in precision medicine and technology to engage with a world-class team on the front lines of health innovation," said Dr. J. Craig Venter, Co-Founder and CEO of Human Longevity, Inc.  "We look forward to welcoming these experts and transforming healthcare together."

The 6-12 month program is open to post graduate scholars and field experts at HLI's locations in San Diego, Mountain View and Singapore.

APPLICATION DETAILS – The deadline for application submissions is September 1, 2015 to [email protected]  Please see for application and program information.

About Human Longevity, Inc.
Human Longevity Inc. (HLI) is the genomics-based, technology-driven company creating the world's largest and most comprehensive database of whole genome, phenotype and clinical data.  HLI is developing and applying large scale computing and machine learning to make novel discoveries to revolutionize the practice of medicine.  A privately held company headquartered in San Diego, CA, HLI was founded in 2013 by pioneers in the fields of genomics and stem cell therapy. HLI will be licensing access to its database, and developing new diagnostics and therapeutics as part of their product offerings.  For more information please visit,

# # #

Media Contact

Katie McCormick Lelyveld, [email protected], (858) 945-8975

Sponsored By Metabolon

Five Translational Insights Key to a Successful First-in-Human (FIH) Study – Metabolite-Based Biomarker Discovery and Validation

Translational success rates from pre-clinical animal studies to human clinical trials remain frustratingly low. Learn how metabolomics helps you bridge between the theoretical & practical, between the function & actual activity of your drug molecule to get you closer to the phenotype, sooner.